Amneal's earnings call reflected strong financial performance and growth prospects, with successful product launches and strategic debt refinancing. Despite some challenges in specific segments, the overall outlook remains positive.

Company Guidance

During Amneal Pharmaceuticals' Second Quarter 2025 Earnings Call, the company reported strong performance metrics, including revenues of $720 million and an adjusted EBITDA of $184 million. Amneal raised its 2025 guidance, projecting revenues between $3 billion to $3.1 billion and adjusted EBITDA in the range of $665 million to $685 million. The company highlighted its diverse growth drivers, such as the CREXONT launch for Parkinson's disease, which is on track to achieve U.S. peak sales between $300 million and $500 million, and the upcoming commercial rollout of Brekiya autoinjector for migraines. Additionally, Amneal emphasized its strategic partnership with Metsera in the GLP-1 space and anticipated strong biosimilar growth, with expectations of having six marketed biosimilars by 2027. The company also highlighted its operational excellence, noting significant gross margin improvements and a reduction in net leverage to 3.7x adjusted EBITDA. The earnings call underscored Amneal's commitment to being America's leading affordable medicines company while maintaining a robust focus on innovation and manufacturing excellence.

Strong Financial Performance

Amneal reported Q2 revenues of $720 million and adjusted EBITDA of $184 million, with a 13% growth in adjusted EBITDA and a 56% increase in adjusted EPS.

Raised 2025 Guidance

Amneal increased its 2025 financial guidance, with adjusted EBITDA raised by $15 million and adjusted EPS by $0.05.

CREXONT's Successful Launch

CREXONT, a treatment for Parkinson's disease, exceeded expectations with a U.S. market share aim of over 3% by year-end and an anticipated peak sales of $300 million to $500 million.

Product Pipeline and Launches

Continued strong pipeline with 20-30 new product launches expected annually, including the Brekiya autoinjector for migraines and biosimilars.

Debt Refinancing

Successfully refinanced $2.7 billion of debt, reducing annual interest costs by $33 million and extending maturities to 2032.

Amneal Pharmaceuticals (AMRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 07, 2025	2025 (Q3)	0.16 / -	0.16	―	―	―
Aug 05, 2025	2025 (Q2)	0.17 / 0.25	0.16	56.25% (+0.09)
May 02, 2025	2025 (Q1)	0.15 / 0.21	0.14	50.00% (+0.07)
Feb 28, 2025	2024 (Q4)	0.15 / 0.12	0.14	-14.29% (-0.02)
Nov 08, 2024	2024 (Q3)	0.13 / 0.16	0.19	-15.79% (-0.03)
Aug 09, 2024	2024 (Q2)	0.15 / 0.16	0.19	-15.79% (-0.03)
May 03, 2024	2024 (Q1)	0.09 / 0.14	0.12	16.67% (+0.02)
Mar 01, 2024	2023 (Q4)	0.09 / 0.14	0.23	-39.13% (-0.09)
Nov 07, 2023	2023 (Q3)	0.13 / 0.19	0.14	35.71% (+0.05)
Aug 04, 2023	2023 (Q2)	0.10 / 0.19	0.19	0.00% (0.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AMRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$7.96	$8.13	+2.14%
May 02, 2025	$7.74	$7.97	+2.97%
Feb 28, 2025	$8.38	$8.67	+3.46%
Nov 08, 2024	$8.61	$8.73	+1.39%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.